1.22
-0.02 (-1.61%)
Penutupan Terdahulu | 1.24 |
Buka | 1.24 |
Jumlah Dagangan | 141,941 |
Purata Dagangan (3B) | 299,665 |
Modal Pasaran | 38,059,000 |
Harga / Jualan (P/S) | 517.80 |
Harga / Buku (P/B) | 1.18 |
Julat 52 Minggu | |
Tarikh Pendapatan | 14 Nov 2024 |
Margin Operasi (TTM) | -57,665.44% |
EPS Cair (TTM) | -1.39 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 4.22% |
Nisbah Semasa (MRQ) | 8.95 |
Aliran Tunai Operasi (OCF TTM) | -33.96 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -20.06 M |
Pulangan Atas Aset (ROA TTM) | -30.91% |
Pulangan Atas Ekuiti (ROE TTM) | -87.96% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Bercampur | |
Stok | Actinium Pharmaceuticals, Inc. | - | - |
AISkor Stockmoo
Konsensus Penganalisis | 0.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 0.5 |
Purata Bergerak Teknikal | -2.5 |
Osilator Teknikal | 2.0 |
Purata | 0.00 |
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 1.79% |
% Dimiliki oleh Institusi | 30.11% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
18 Nov 2024 | Pengumuman | Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 |
04 Nov 2024 | Pengumuman | Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |